Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood.
Authors
Jammeh, Emmanuel
Swietlik, Emilia M
Otero, Pablo
Pandya, Divya
Mascarenhas, Thomas S
Romanoski, Casey E
Rischard, Franz
Garcia, Joe GN
Yuan, Jason X-J
An, Tae-Hwi Schwantes
Desai, Ankit A
Coghlan, Gerry
Lordan, Jim
Corris, Paul A
Condliffe, Robin
Kiely, David G
Church, Colin
Pepke-Zaba, Joanna
Toshner, Mark
Wort, Stephen
Morrell, Nicholas W
UK National PAH Cohort Study Consortium
Publication Date
2021-12-07Journal Title
Nat Commun
ISSN
2041-1723
Publisher
Springer Science and Business Media LLC
Volume
12
Issue
1
Language
en
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
Kariotis, S., Jammeh, E., Swietlik, E. M., Pickworth, J. A., Rhodes, C. J., Otero, P., Wharton, J., et al. (2021). Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood.. Nat Commun, 12 (1) https://doi.org/10.1038/s41467-021-27326-0
Abstract
Idiopathic pulmonary arterial hypertension (IPAH) is a rare but fatal disease diagnosed by right heart catheterisation and the exclusion of other forms of pulmonary arterial hypertension, producing a heterogeneous population with varied treatment response. Here we show unsupervised machine learning identification of three major patient subgroups that account for 92% of the cohort, each with unique whole blood transcriptomic and clinical feature signatures. These subgroups are associated with poor, moderate, and good prognosis. The poor prognosis subgroup is associated with upregulation of the ALAS2 and downregulation of several immunoglobulin genes, while the good prognosis subgroup is defined by upregulation of the bone morphogenetic protein signalling regulator NOG, and the C/C variant of HLA-DPA1/DPB1 (independently associated with survival). These findings independently validated provide evidence for the existence of 3 major subgroups (endophenotypes) within the IPAH classification, could improve risk stratification and provide molecular insights into the pathogenesis of IPAH.
Keywords
Article, /631/114/1386, /631/114/2404, /631/1647/2217, /692/4019/592/75, /38/91, /49/39, article
Sponsorship
Medical Research Council (MR/K020919/1)
British Heart Foundation (None)
British Heart Foundation (SP/18/10/33975)
Identifiers
s41467-021-27326-0, 27326
External DOI: https://doi.org/10.1038/s41467-021-27326-0
This record's URL: https://www.repository.cam.ac.uk/handle/1810/331801
Rights
Licence:
http://creativecommons.org/licenses/by/4.0/
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: support@repository.cam.ac.uk